Year 3
During the past funding period, we have accomplished the established milestones. We have compared the genomic stability of iPSCs generated with various approaches. We have developed a genetic approach to eliminate the teratomas risk associated with undifferentiated pluripotent stem cells. We have evaluated the immunogenicity of cells derived from human iPSCs.